With a median five-year follow-up, failure free survival at one, three, and five years was 99%, 92%, and 88% respectively, equivalent to that achieved with surgery. Metastasis-free, cancer-specific, and overall survival at five years was 98%, 100%, and 99% respectively.
The study additionally reports that 98% of men maintained pad-free urinary continence after their procedure and 85% maintained erectile function, both material improvements over that seen with surgery and radiation therapy.
The study concluded that failure free survival with HIFU can be equivalent to that of surgery but with a side effect profile far more beneficial to the patient's quality of life post-procedure.
Sonablate has 510(K) clearance in the US and is indicated for the transrectal high intensity focused ultrasound ablation of prostatic tissue.
SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project